Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 42, Issue 2, 2017, Pages 333-339

  Polepally, Akshanth R ^a   Badri, Prajakta S ^a   Eckert, Doerthe ^a   Mensing, Sven ^a   Menon, Rajeev M ^a  

^a ABBVIE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DASABUVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; RIBAVIRIN; ABT-267; ABT-333; ABT-450; ANILIDE; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; MACROCYCLIC COMPOUND; RITONAVIR; SULFONAMIDE; URACIL;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; ASIAN; BODY WEIGHT; CHRONIC HEPATITIS C; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG EXCRETION; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN TISSUE; KIDNEY DISEASE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PHARMACOKINETICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; PREDICTION; SEX; URINARY EXCRETION; ADOLESCENT; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; COMBINATION DRUG THERAPY; COMPLICATION; DOSE RESPONSE; GENETICS; GENOTYPE; HEPACIVIRUS; ISOLATION AND PURIFICATION; KIDNEY FAILURE; KIDNEY FUNCTION TEST; META ANALYSIS; MIDDLE AGED; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANILIDES; ANTIVIRAL AGENTS; AREA UNDER CURVE; CARBAMATES; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; KIDNEY FUNCTION TESTS; MACROCYCLIC COMPOUNDS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RENAL INSUFFICIENCY; RIBAVIRIN; RITONAVIR; SULFONAMIDES; URACIL; YOUNG ADULT;

EID: 84966565215     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-016-0341-6     Document Type: Article

References (23)

1. Bunchorntavakul C, Tanwandee T. Treatment of chronic hepatitis C in special populations. Gastroenterol Clin N Am. 2015;44:883–900.
2. Noureddin M, Ghany MG. Pharmacokinetics and pharmacodynamics of peginterferon and ribavirin: implications for clinical efficacy in the treatment of chronic hepatitis C. Gastroenterol Clin North Am. 2010;39:649–58.
3. Bunchorntavakul C, Maneerattanaporn M, Chavalitdhamrong D. Management of patients with hepatitis C infection and renal disease. World J Hepatol. 2015;7:213–25.
4. Berenguer M. Treatment of chronic hepatitis C in hemodialysis patients. Hepatology. 2008;48:1690–9.
5. Bunchorntavakul C, Reddy KR. Ribavirin: how does it work and is it still needed? Curr Hepat Rep. 2011;10:168–78.
6. Kiser JJ, Burton JR, Everson GT. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013;10:596–606.
7. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. http://www.easl.eu/medias/cpg/HEPC-2015/Full-report.pdf. Accessed 9 May 2016.
8. American Association for the Study of Liver Diseases. HCV guidance: recommendations for testing, managing, and treating hepatitis C. 2016. http://www.hcvguidelines.org/full-report-view. Accessed 9 May 2016.
9. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594–603.
10. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1604–14.
11. Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147:359–65.
12. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973–82.
13. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983–92.
14. Lalezari J, Sullivan JG, Varunok P, Galen E, Kowdley KV, Rustgi V, et al. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. J Hepatol. 2015;63:364–9.
15. Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) [US prescribing information]. North Chicago: AbbVie Inc.; 2015.
16. Khatri A, Dutta S, Marbury T, Preston RA, Rodrigues L, Wang H, et al. The pharmacokinetics and safety of the direct acting antiviral regimen of ABT-450/r, ombitasvir with/without dasabuvir in subjects with mild, moderate and severe renal impairment compared to subjects with normal renal function. Hepatology. 2014;60(Suppl 1):320A.
17. Mensing S, Sharma S, Eckert D, Polepally A, Khatri A, Podsadecki T, et al. Pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in subjects with HCV genotype 1 infection in phase 3 studies. J Hepatol. 2015;62(S2):S644.
18. Mensing S, Sharma S, Eckert D, Polepally A, Khatri A, Podsadecki T, Awni W, Menon R, Dutta S. Pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in subjects with HCV genotype 1 infection in phase 3 studies [abstract no. P0820]. J Hepatol. 2016; 62:S644. http://www.journal-of-hepatology.eu/article/S0168-8278(15)31023-0/pdf. Accessed 9 May 2016.
19. Copegus (ribavirin) [US prescribing information]. South San Francisco, CA: Genentech; 2015.
20. Sullivan GJ, Rodrigues-Torres M, Lawitz E, Poordad F, Kapoor M, Campbell A, et al. ABT-267 combined with pegylated interferon alpha-2a/ribavirin in genotype 1 (GT1) HCV-infected treatment-naive subjects: 12 week antiviral and safety analysis. J Hepatol. 2012;56:S480.
21. Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med. 2013;368:45–53.
22. Zollner G, Fickert P, Silbert D, Fuchsbichler A, Marschall HU, Zatloukal K, et al. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol. 2003;38:717–727.
23. More VR, Cheng Q, Donepudi AC, Buckley DB, Lu ZJ, Cherrington NJ, et al. Alcohol cirrhosis alters nuclear receptor and drug transporter expression in human liver. Drug Metab Dispos. 2013;41:1148–1155.